Genfit Gestione

Gestione criteri di controllo 4/4

Genfit Il CEO è M. Prigent, nominato in Sep2019, e ha un mandato di 5.17 anni. la retribuzione annua totale è € 664.22K, composta da 59.3% di stipendio e 40.7% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.062% delle azioni della società, per un valore di € 124.68K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 7.4 anni.

Informazioni chiave

M. Prigent

Amministratore delegato

€664.2k

Compenso totale

Percentuale dello stipendio del CEO	59.3%
Mandato del CEO	5.2yrs
Proprietà del CEO	0.06%
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	7.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di M. Prigent rispetto agli utili di Genfit?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	€22m
Mar 31 2024	n/a	n/a	-€3m
Dec 31 2023	€664k	€394k	-€29m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€34m
Mar 31 2023	n/a	n/a	-€29m
Dec 31 2022	€632k	€375k	-€24m
Sep 30 2022	n/a	n/a	€12m
Jun 30 2022	n/a	n/a	€48m
Mar 31 2022	n/a	n/a	€58m
Dec 31 2021	€562k	€325k	€67m
Sep 30 2021	n/a	n/a	€14m
Jun 30 2021	n/a	n/a	-€39m
Mar 31 2021	n/a	n/a	-€70m
Dec 31 2020	€455k	€325k	-€101m
Sep 30 2020	n/a	n/a	-€84m
Jun 30 2020	n/a	n/a	-€67m
Mar 31 2020	n/a	n/a	-€66m
Dec 31 2019	€325k	€95k	-€65m

Compensazione vs Mercato: La retribuzione totale di M. ($USD 691.68K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 782.05K ).

Compensazione vs guadagni: La retribuzione di M. è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

M. Prigent (55 yo)

5.2yrs

Mandato

€664,224

Compensazione

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.4yrs	€359.01k	0.093% € 189.2k
M. Prigent	Chief Executive Officer	5.2yrs	€664.22k	0.062% € 124.7k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Thomas Baetz	Chief Financial Officer	3.6yrs	Nessun dato	Nessun dato
Pascal Caisey	Chief Operating Officer	2.7yrs	Nessun dato	0.0095% € 19.2k
Meriam Kabbaj	Chief Technology Officer	1.9yrs	Nessun dato	Nessun dato
Dean Hum	Chief Scientific Officer	2.8yrs	€795.03k	0.021% € 41.8k
Jean-Christophe Marcoux	Chief Corporate Affairs Officer	1.7yrs	Nessun dato	0.0094% € 19.0k
Laurent Lannoo	Corporate Secretary & Director of Legal Affairs	16.8yrs	Nessun dato	0.023% € 45.6k
Stefanie Magner	Chief Compliance Officer & Executive VP of International Legal Affairs	3.7yrs	Nessun dato	0.0055% € 11.2k
Emilie Desodt	Executive Vice President of Human Resources	2.7yrs	Nessun dato	0.0035% € 7.1k
Sakina Sayah-Jeanne	Executive VP of Research & Translational Science	1.6yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

52.5yo

Età media

Gestione esperta: Il team dirigenziale di XUP è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jean-Francois Mouney	Co-Founder & Chairman of the Board	7.4yrs	€359.01k	0.093% € 189.2k
Bart Staels	Co-Founder & Chairman of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Philippe Moons	Board Observer	3.8yrs	€7.63k	0.0021% € 4.2k
Florence Séjourné	Director	7.4yrs	Nessun dato	Nessun dato
Scott L. Friedman	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Arun Sanyal	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Michael Trauner	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Catherine Larue	Independent Director	7.4yrs	€43.60k	Nessun dato
Vlad Ratziu	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Anne-Helene Monsellato	Independent Director	7.4yrs	€39.24k	Nessun dato
Katherine Kalin	Independent Director	4.3yrs	€39.24k	0.010% € 20.3k
Eric Baclet	Independent Vice-Chairman of the Board	4.3yrs	€47.96k	0.0024% € 4.9k

7.4yrs

Durata media

62.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di XUP sono considerati esperti (durata media dell'incarico 7.4 anni).

Genfit Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

GENFIT Announces Board Changes

Genfit SA, Annual General Meeting, May 28, 2021

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

Recent updates

Investor sentiment deteriorates as stock falls 19%

Investor sentiment improves as stock rises 20%

First half 2024 earnings released: EPS: €0.61 (vs €0.42 loss in 1H 2023)

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

New minor risk - Share price stability

Full year 2023 earnings released: €0.58 loss per share (vs €0.48 loss in FY 2022)

Insufficient new directors

Genfit S.A., Annual General Meeting, May 22, 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

GENFIT Announces Publication in Nature Medicine Confirming the Performance of Its Nash Diagnostic Technology

First half 2023 earnings released: €0.42 loss per share (vs €0.21 loss in 1H 2022)

New minor risk - Profitability

Genfit S.A. Announces the Publication of New Data on the Clinical Performance of NIS2+(TM) in Older Patients in Hepatology Communications

New minor risk - Profitability

New minor risk - Share price stability

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week as part of its ACLF Program

Full year 2022 earnings released: €0.48 loss per share (vs €1.50 profit in FY 2021)

Genfit S.A. to Report First Half, 2023 Results on Sep 20, 2023

Genfit S.A. (ENXTPA:GNFT) acquired Versantis AG for approximately CHF 110 million.

First half 2022 earnings released: €0.21 loss per share (vs €0.21 profit in 1H 2021)

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG for approximately CHF 110 million.

Genfit S.A. (ENXTPA:GNFT) agreed to acquire Versantis AG from a group of investors for approximately CHF 110 million.

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: €1.51 (vs €2.61 loss in FY 2020)

Forecast to breakeven in 2022

First half 2021 earnings released: EPS €0.21 (vs €1.36 loss in 1H 2020)

GENFIT Presents New NIS4® Data in NASH at the International Liver Congress™ and the 81St Scientific Sessions of the American Diabetes Association

GENFIT Announces the Launch of NASHnext®, a Novel, Noninvasive Diagnostic Test for Nonalcoholic Steatohepatitis

Full year 2020 earnings released: €2.60 loss per share (vs €1.76 loss in FY 2019)

Full year 2020 earnings released

GENFIT Announces Board Changes

Genfit SA to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: €5.19

Genfit SA, Annual General Meeting, May 28, 2021

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Pascal Caisey and Philippe Motté Join the Executive Committee of GENFIT

New 90-day high: €4.75

Robbins LLP Announces That Purchaser of Genfit SA American Depository Shares Filed Class Action Complaint Against the Company and Its Officers and Directors for Alleged Violations of the Securities Act of 1933

Genfit Presents New Data at AASLD The Liver Meeting Digital Experience™

Genfit and Labcorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

First half earnings released

GENFIT Announces First Patient First Visit for ELATIVE Phase 3 Study Evaluating Elafibranor in PBC

Genfit SA to Report First Half, 2020 Results on Sep 30, 2020

New 90-day low: €3.59

New 90-day low - €3.99

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media